

CITATION REPORT

List of articles citing

Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database

DOI: 10.1007/s11060-020-03687-2

Journal of Neuro-Oncology, 2021, 152, 135-144.

Source: <https://exaly.com/paper-pdf/78852040/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
27	Immune checkpoint inhibitors increase risk of neurological disorders. <i>Reactions Weekly</i> , 2021 , 1838, 6-6		0
26	Neuromuscular complications of cancer therapy. <i>Current Opinion in Neurology</i> , 2021 , 34,	7.1	1
25	Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 693279	5.3	0
24	Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases. <i>BioMed Research International</i> , 2021 , 2021, 9800488	3	1
23	How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
22	Autoimmune and Inflammatory Encephalopathies as Complications of Cancer. 2022 , 430-459		
21	Harnessing big data to characterize immune-related adverse events.. <i>Nature Reviews Clinical Oncology</i> , 2022 ,	19.4	1
20	Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma.. <i>BMC Rheumatology</i> , 2022 , 6, 10	2.9	0
19	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review.. <i>Academic Radiology</i> , 2022 ,	4.3	0
18	Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review.. <i>Journal of Neuro-Oncology</i> , 2022 ,	4.8	0
17	Adverse drug reactions associated with immune checkpoint inhibitors: an exploratory nested case-control study in a historical cohort. <i>Therapie</i> , 2022 ,	3.8	
16	Multi-organs perioperative immune-related adverse events and postoperative bronchial anastomotic fistula in a patient receiving neoadjuvant immunotherapy with NSCLC. <i>Thoracic Cancer</i> ,	3.2	0
15	Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. 2022 , 174, 113-120		0
14	Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. 2022 , 175, 224-235		0
13	Neurology. 2022 , 215-230		0
12	Urinary incontinence as a possible signal of neuromuscular toxicity during immune checkpoint inhibitor treatment: Case report and retrospective pharmacovigilance study. 12,		1
11	Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. 13,		0

- 10 Characteristic cerebrospinal fluid findings in immune checkpoint inhibitor-related peripheral neuropathy: A case report. **2023**, 374, 578010
- 9 The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects.
- 8 Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review. 13,
- 7 Myasthenia Gravis Induced by Immune Checkpoint Inhibitors: An Emerging Neurotoxicity in Neuro-Oncology Practice: Case Series. **2023**, 12, 130
- 6 B.infantis enhances immunotherapy for Guillain-Barre syndrome through regulating PD-1. **2023**, 23,
- 5 Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. 14,
- 4 Pembrolizumab-Induced Acral Vasculitis. **2023**, 46, 107-110
- 3 Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies. **2023**, 28,
- 2 Effect of age on the risk of immune-related adverse events in patients receiving immune checkpoint inhibitors.
- 1 PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). 1-11